IDEX CORP /DE/ (IEX) Form 10-Q — Oct 28, 2026
IDEX Corporation reported Q3 2026 net sales of $951.7 million, up 8% on both a reported and organic basis, with reported diluted EPS of $1.95 up 15% and adjusted diluted EPS of $2.33 up 15% year over year. Growth was led by the Health & Science Technologies segment (+14% sales, 110 bps margin expansion), driven by AI-driven demand for data center power, semiconductor, and space and defense markets. The company also refinanced its revolver with a new $800 million facility maturing September 2031. IDEX returned $74.6 million via buybacks and $54.0 million via dividends in the quarter, with $699.7 million remaining under repurchase authorization.
Key figures
- Eps
- 1.95
- Revenue
- 951.7
- Net Income
- 144.1
- Total Debt
- 1759
- Revenue Yoy
- 8%
- Cash Position
- 602.1
- Shares Outstanding
- 73452801
- Buybacks 9m
- 227
- Gross margin q3
- 45.1%
- Dividends paid 9m
- 160.7
- Free cash flow 9m
- 477.3
- Adjusted ebitda q3
- 264.8
- Net leverage ratio
- 1.39 to 1
- Operating income q3
- 208
- Dividend per share q3
- 0.73
- Operating cash flow 9m
- 543.2
- Adjusted diluted eps q3
- 2.33
- Interest coverage ratio
- 14.69 to 1
- Organic sales growth q3
- 8%
- Adjusted diluted eps growth
- 15%
- Revolving facility availability
- 637.7
- Repurchase authorization remaining
- 699.7
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.